Efficacy by definitions of success in patients with long-term persistent atrial fibrillation
| Number of patients 89 . | First treatment PVAC/MASC/MAAC . | Second treatment PVAC/MASC/MAAC . | |
|---|---|---|---|
| . | n = patients/total (%) . | n = patients/total (%) . | |
| Absence of AF/flutter/tachycardiaa, and patients were off class I or III AADs, 12 months after the (last) PVAC/MASC/MAAC ablation | 32/89 (36) | 6/15 (40) | |
| Paroxysmal AF after treatment | 15/89 (17) | 4/15 (27) | |
| DCCV | 12/89 (13) | 0/15 (0) | |
| No change | 30/89 (34) | 5/15 (33) | |
| Additional procedure | 23/89 (26) | 3/15 (20) | |
| Redo PVAC/MASC/MAAC | 15/23 | – | |
| Cumulative AF freedom | Patients | n = patients/total | (%) |
| First treatment with PVAC/MASC/MAAC | n = 89 | 32/89 | 36 |
| Including DCCV | n = 12 | 44/89 | 49 |
| Second treatment with PVAC/MASC/MAAC | n = 15 | 50/89 | 56 |
| Change to paroxysmal AF (cumulative after one or two treatments with PVAC/MASC/MAAC) | n = 18 | 18/89 | 20 |
| No change (cumulative after one or two treatments with PVAC/MASC/MAAC) | n = 21 | 21/89 | 24 |
| Number of patients 89 . | First treatment PVAC/MASC/MAAC . | Second treatment PVAC/MASC/MAAC . | |
|---|---|---|---|
| . | n = patients/total (%) . | n = patients/total (%) . | |
| Absence of AF/flutter/tachycardiaa, and patients were off class I or III AADs, 12 months after the (last) PVAC/MASC/MAAC ablation | 32/89 (36) | 6/15 (40) | |
| Paroxysmal AF after treatment | 15/89 (17) | 4/15 (27) | |
| DCCV | 12/89 (13) | 0/15 (0) | |
| No change | 30/89 (34) | 5/15 (33) | |
| Additional procedure | 23/89 (26) | 3/15 (20) | |
| Redo PVAC/MASC/MAAC | 15/23 | – | |
| Cumulative AF freedom | Patients | n = patients/total | (%) |
| First treatment with PVAC/MASC/MAAC | n = 89 | 32/89 | 36 |
| Including DCCV | n = 12 | 44/89 | 49 |
| Second treatment with PVAC/MASC/MAAC | n = 15 | 50/89 | 56 |
| Change to paroxysmal AF (cumulative after one or two treatments with PVAC/MASC/MAAC) | n = 18 | 18/89 | 20 |
| No change (cumulative after one or two treatments with PVAC/MASC/MAAC) | n = 21 | 21/89 | 24 |
aLasting >30 s, on one of the recordings after the 3 month blanking period by repeated 12-lead ECG, event monitoring and Holter.
AAD, anti-arrhythmic drug; AF, atrial fibrillation; DCCV, direct current cardioversion; RF radiofrequency; PVAC, pulmonary vein ablation catheter; MASC, multi-array septal catheter; MAAC, multi-array ablation catheter.
Efficacy by definitions of success in patients with long-term persistent atrial fibrillation
| Number of patients 89 . | First treatment PVAC/MASC/MAAC . | Second treatment PVAC/MASC/MAAC . | |
|---|---|---|---|
| . | n = patients/total (%) . | n = patients/total (%) . | |
| Absence of AF/flutter/tachycardiaa, and patients were off class I or III AADs, 12 months after the (last) PVAC/MASC/MAAC ablation | 32/89 (36) | 6/15 (40) | |
| Paroxysmal AF after treatment | 15/89 (17) | 4/15 (27) | |
| DCCV | 12/89 (13) | 0/15 (0) | |
| No change | 30/89 (34) | 5/15 (33) | |
| Additional procedure | 23/89 (26) | 3/15 (20) | |
| Redo PVAC/MASC/MAAC | 15/23 | – | |
| Cumulative AF freedom | Patients | n = patients/total | (%) |
| First treatment with PVAC/MASC/MAAC | n = 89 | 32/89 | 36 |
| Including DCCV | n = 12 | 44/89 | 49 |
| Second treatment with PVAC/MASC/MAAC | n = 15 | 50/89 | 56 |
| Change to paroxysmal AF (cumulative after one or two treatments with PVAC/MASC/MAAC) | n = 18 | 18/89 | 20 |
| No change (cumulative after one or two treatments with PVAC/MASC/MAAC) | n = 21 | 21/89 | 24 |
| Number of patients 89 . | First treatment PVAC/MASC/MAAC . | Second treatment PVAC/MASC/MAAC . | |
|---|---|---|---|
| . | n = patients/total (%) . | n = patients/total (%) . | |
| Absence of AF/flutter/tachycardiaa, and patients were off class I or III AADs, 12 months after the (last) PVAC/MASC/MAAC ablation | 32/89 (36) | 6/15 (40) | |
| Paroxysmal AF after treatment | 15/89 (17) | 4/15 (27) | |
| DCCV | 12/89 (13) | 0/15 (0) | |
| No change | 30/89 (34) | 5/15 (33) | |
| Additional procedure | 23/89 (26) | 3/15 (20) | |
| Redo PVAC/MASC/MAAC | 15/23 | – | |
| Cumulative AF freedom | Patients | n = patients/total | (%) |
| First treatment with PVAC/MASC/MAAC | n = 89 | 32/89 | 36 |
| Including DCCV | n = 12 | 44/89 | 49 |
| Second treatment with PVAC/MASC/MAAC | n = 15 | 50/89 | 56 |
| Change to paroxysmal AF (cumulative after one or two treatments with PVAC/MASC/MAAC) | n = 18 | 18/89 | 20 |
| No change (cumulative after one or two treatments with PVAC/MASC/MAAC) | n = 21 | 21/89 | 24 |
aLasting >30 s, on one of the recordings after the 3 month blanking period by repeated 12-lead ECG, event monitoring and Holter.
AAD, anti-arrhythmic drug; AF, atrial fibrillation; DCCV, direct current cardioversion; RF radiofrequency; PVAC, pulmonary vein ablation catheter; MASC, multi-array septal catheter; MAAC, multi-array ablation catheter.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
